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Chemokine Receptors: Minireview
Keys to AIDS Pathogenesis?
This major advance followed closely on the heels of the
discovery that an activity in lymphocyte supernatants
that inhibited HIV replication consisted of three chemo-
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Departments of Microbiology and Pathology kines of the CC or b class, RANTES, MIP-1a, and MIP-
1b. These polypeptides were shown to inhibit replicationNew York University Medical Center
New York, New York 10016 of macrophage-tropic, but not T cell line±tropic, strains
of HIV-1 (Cocchi et al., 1995). Together, these findings
set the stage for the demonstration that CCR5, the re-
ceptor for the three b-chemokines, is the major cofactorOnly two years ago, the rapidly expanding families of
required for entry of macrophage-tropic strains of HIV-1chemokines and of their seven-transmembrane G pro-
into CD41 cells (for review, see Weiss and Clapham,tein±coupled receptors (GPCRs) occupied an important,
1996, and references therein). Although other membersbut not widely recognized, area of biology (reviewed in
of this GPCR family have also been shown to shepherdPremack and Schall, 1996). The discoveries that chemo-
in various strains of virus, CCR5 and/or CXCR4 remainkines can block HIV replication and that their receptors
the receptors used by all known strains of HIV-1. Thehave essential functions in fusion of HIV to target cells
current nomenclature for receptor tropism is R5 (forpropelled this field into the limelight, and raised expecta-
CCR5-tropic virus), X4 (for CXCR4-tropic virus), andtions that chemokines might hold the key to understand-
R5X4 for dual-tropic virus. The expression of CCR5 oningHIV-mediated pathogenesis, both in the immune sys-
macrophages and primary T cells, but not on trans-tem and the central nervous system. Although this
formed T cell lines, explains the tropism of most R5promise has yet to be fulfilled, much has been learned
viruses (Figure 1). The reason why X4 viruses replicatesince the early exciting findings, and it is now possible
in primary and transformed T cells, but not in monocytesto formulate questions with considerably greater clarity.
and macrophages, is less clear, because all of theseThis review will focus on some recent advances and on
cells express CXCR4 (Figure 1). It is possible that viraloutstanding questions regarding the role of chemokine
entry into macrophages is intact, but that replication isreceptor family members in the primate lentiviral replica-
blocked due to the inability of CXCR4 to transmit ation cycle and in pathogenesis.
requisite signal. Alternatively, entry may fail because ofChemokine Receptors as Determinants
cell type±specific restrictions in conformation of CXCR4of Viral Tropism
or in its ability to associate with other proteins. This isThe discovery that CD4 is a receptor for HIV and inter-
a particularly important issue because, as discussedacts with high affinity with the viral envelope glycopro-
below, macrophage infection is likely to be importanttein was one of the major findings in the wake of the
for transmission of the virus.discovery of the virus in the mid-1980s. It was soon
The basis for the tropism of different envelope glyco-recognized, however, that expression of the CD4 glyco-
proteins for either CCR5 or CXCR4 resides in the abilityprotein is not always sufficient to permit infection. For
of gp120 to interact directly with these receptors (re-example, rodent cell lines transfected with human CD4
viewed byBieniasz and Cullen, 1998). Envelope subunitswere refractory to viral entry mediated by the HIV enve-
from R5 strains, but not from X4 strains, compete forlope glycoprotein, but not by heterologous envelopes
binding of radiolabeled chemokine to CCR5, but thisthat utilized different receptors on the same cells. A
interaction requires prior binding of gp120 to CD4. Com-physiologically more relevant example was the dichot-
plexes of soluble CD4 and envelope glycoprotein fromomy in tropism that distinguished viral strains adapted
either HIV or the closely related simian immunodefi-for growth in transformed T cells from those maintained
ciency virus (SIV) also bind to CCR5 on CD42 cells,in peripheral blood mononuclear cells. The former could
explaining earlier observations of soluble CD4-mediatedreplicate in transformed T cell lines and activated pri-
enhancement of SIV and HIV-2 infectivity. A soluble formmary T-helper cells, but not in monocytes and macro-
of CD4 containing only the N-terminal two Ig-like do-phages, even though all these cell types express CD4.
mains was also reported to compete for binding ofThe latter replicated well in macrophages and T-helper
chemokine to CCR5. These findings suggest that bind-cells, but not in transformed T cell lines. The differences
ing of gp120 to CD4 induces a conformational changein tropism between these viruses mapped to sequences
that increases the affinity of gp120 for the appropriatein the gp120 subunit of the envelope glycoprotein, par-
chemokine receptor. Alternatively, CD4 and gp120 inde-ticularly to the solvent-accessible V3 domain. These ob-
pendently have low affinities for CCR5, but have highservations suggested that, in addition to CD4, other
avidity when they are complexed with each other. Bind-molecules would have important roles in species-spe-
ing to CCR5 is dependent on the V3 domain sequencecific and cell type-specific tropism of HIV (for review,
in gp120, but it remains unclear if there are direct interac-see Clapham et al., 1993).
tions between V3 and the chemokine receptor.An explanation for these findings remained elusive for
The interactions of HIVs with CXCR4 may differ frommany years and came only after the expression cloning
those with CCR5, since gp120 from an X4 strain wasof a GPCR, now known as the chemokine receptor
found to bind toCXCR4 in the absence of surface-boundCXCR4, as a cofactor required for entry of T cell line±
tropic virus into CD41 murine cells (Feng et al., 1996). or soluble CD4. Interaction of this envelope glycoprotein
Cell
678
cytoplasmic domain sequences in CCR5. However,
there is evidence that binding of envelope glycoprotein
to the receptors can mimic binding of chemokines, re-
sulting in activation of the heterotrimeric G proteins,
Ca21 fluxing, and tyrosine phosphorylation (Davis et al.,
1997; Weissman et al., 1997). Such signals may have
important roles in postentry events in retroviral replica-
tion and may also have pathogenic consequences in
uninfected cells (see below). It is not yet known whether
CD4 and the chemokine receptors normally interact in
the plane of the membrane and if such complexes have
specific signaling properties following binding of gp120.
Chemokine Receptors in TransmissionFigure 1. Basis of HIV-1 Cellular Tropism
and Disease ProgressionPrevious nomenclature for viral tropism is noted at the bottom.
Macrophage-tropic viruses were also named NSI (non-syncytium- Examination of the phenotypes of HIV strains sampled
inducing in T cell lines), whereas T cell line±tropic viruses were at different times in the course of infection showed that
named SI (syncytium-inducing). These viruses are now named R5 isolates present during the early acute phase were mac-
and X4, respectively. rophage-tropic, now known to be CCR5-specific. The
significance of this finding was magnified by thestartling
with CD4 is nevertheless required to activate its fuso- discovery that a homozygous 32 bpdeletion in the CCR5
genic potential. There are rare examples, however, in gene, found in about 1% of Caucasians, confers resis-
which CD4 is not even required for primate lentiviral tance to acquisition of HIV infection (reviewed in Stew-
entry. A strain of HIV-2 selected for growth in CD42 cells art, 1998). Viral strains with X4 or R5X4 tropism usually
was found to infect by utilizing CXCR4 alone (Endres et arise only later in the course of infection and are preva-
al., 1996), as was a spontaneously arising mutant HIV-1, lent during progression to disease. A major unanswered
in which the phenotype was conferred by seven muta- question is why X4 strains are rarely, if ever, transmitted
tions in gp120, including some in the V3 domain (Du- between individuals. Rare CCR5D32 homozygotes have
monceaux et al., 1998, and references therein). In addi- been reported among those infected, but it is unclear
tion, several strains of neurovirulent SIV can infect CD42 if they had acquired virus by way of CXCR4. During
cells through CCR5 (see below), and SIV gp120 can progression of immunodeficiency and neurological dis-
interact with rhesus CCR5 in the absence of CD4. The ease, there is a general broadening of virus tropism,
envelope glycoproteins of these viruses may already be with a variable degree of usage of additional chemokine
in a fusion-competent conformation that only requires receptors or orphan GPCRs (see Table 1), and these
interaction with the chemokine receptor for initiation of or other molecules yet to be defined may have been
gp41-mediated fusion of lipid bilayers (reviewed by exploited in place of CCR5 during transmission. As
Chan and Kim, 1998 [this issue of Cell]). noted above, in contrast to CCR5-tropic viruses, X4
These results indicate that the chemokine receptor is strains cannot replicate in macrophages. It is possible
the primary receptor that both binds envelope glycopro- that for HIV to evade early immune surveillance, particu-
tein and triggers fusion. CD4 plays important roles, both larly by cytotoxic T cells, it needs to replicate in macro-
to concentrate virus at the surface of the cell (through phages or dendritic cells before spreading to T lympho-
high-affinity interaction with gp120) and to facilitate the cytes. Even if this is a requirement for establishment of
subsequent essential interaction with the chemokine infection, it is surprising that alternate tropisms are so
receptor. However, in contrast to the CD4-independent heavily disfavored in transmission, particularly whenone
entry described above, there is no example of infection considers the adaptability that HIV displays in its evolu-
that is independent of GPCRs. Because the interaction tion in vivo to expanded receptor tropism. This observa-
of gp120 with CD4 was the first to be discovered, the tion suggests that CCR5 isexpressed ina key population
chemokine receptors are now commonly referred to as of cells, in which other GPCR family members that could
HIV ªcoreceptors.º It may be more appropriate to con- potentially be used by HIV are absent; or that CCR5 is
sider CD4 as the rightful coreceptor, just as it is a core- endowed with unique biological properties, such as the
ceptor in T cell antigen receptor±mediated signaling. ability to transduce signals that may enhance viral repli-
Numerous studies have mapped regions of chemo- cation. It is also possible that expression of the CXCR4
kine receptors required for their HIV or SIV receptor ligand, SDF-1, in the lymphoid stroma inhibits transmis-
function (reviewed in Bieniasz and Cullen, 1998). The sion of X4 strains.
general consensus is that sequences in multiple regions Neurological Disease. A significant proportion of HIV-
of the receptors, including the N terminus and the extra- infected patients develop neurological disease, but the
cellular loops, contribute to the interaction with enve- pathogenic mechanism remains obscure. For example,
lope glycoproteins. Moreover, viruses appear to have it is not known whether neuronal cell death is due to
evolved to be flexible in these interactions, since diverse direct infection of these cells or to indirect effects sec-
strains differ in their relative dependence on receptor ondary to interaction of neurons with viral or cellular
domains. Coupling of the receptors to the heterotrimeric products released by infected cells. The cells thought
G proteins appears to be dispensable for the process to transport the virus into the CNS are the monocyte-
of viral entry, as shown both through the use of pertussis derived microglial cells, which express CD4 as well as
CCR5 and CCR3. These chemokine receptors have beentoxin blockade and through mutagenesis of the relevant
Minireview
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Table 1. Chemokine Receptor Family Members' Known Function as Receptors in HIV and SIV Entry
Receptor Ligand Expression Pattern Viral Usage
Major Receptors
CCR3 Eotaxin, MCP-3, MCP-4, RANTES Eosinophils, Microglia, Th2 cells HIV-1 (minor for HIV-2)
CCR5 MIP-1a, MIP-1b, RANTES Monocytes, T cells HIV-1, HIV-2, SIV
CXCR4 SDF-1 Lymphocytes, Macrophages, Brain HIV-1 (minor for HIV-2)
BOB/GPR15 ? T cells, Colon SIV, HIV-2 (minor for HIV-1)
Bonzo/STRL33/TYMSTR ? T cells, Monocytes, Placenta SIV, HIV-2 (minor for HIV-1)
Minor Receptors
CCR2 MCP-1, MCP-3 Monocytes, T cells HIV-1, HIV-2
CCR8 I-309 Monocytes, Thymocytes HIV-1, SIV
CX3CR1 (V28) Fractalkine/Neurotactin Lymphocytes, Brain HIV-1, HIV-2
GPR1 ? Macrophages SIV
The ªmajorº receptors have all been tested in viral infectivity assays with multiple strains. Some of the ªminorº receptors have been tested
mainly in cell fusion assays, which may not always be representative of viral infectivity.
proposed to be important for infection of microglial cells signals that dictate postfusion events in the retroviral
replication cycle. It remains to be determined whetherand, presumbably, for the development of AIDS demen-
the observations with the different strains of SIV are duetia, although evidence also points to the possible use
to differences in gp120 interaction with CCR5 or withof yet another receptor expressed on these cells (He et
other macrophage surface molecules, possibly otheral., 1997). There is also strong evidence that some HIV-1
members of the chemokine receptor family.and SIV strains can infect brain capillary endothelial cells
Genetic Factors in Disease Progressionthrough a CD4-independent mechanism which, for SIV
The discovery of resistance to infection conferred byentry, involves CCR5 (Edinger et al., 1997). These results
the homozygous CCR5D32 mutation has spurred furthersuggest an alternate route for dissemination of neuropa-
genetic studies to determine if mutations in chemokinesthogenic strains to the central nervous system and also
or their receptors may influence transmission and pro-raise the possibility that HIV envelopeglycoproteins may
gression to immunodeficiency (Stewart, 1998, and refer-interact directly with chemokine receptors in the brain.
ences therein). Heterozygosity for the CCR5D32 muta-Such CD4-independent interactions may influence sig-
tion has been shown to delay progression to disease,naling pathways and may thus explain previous obser-
as have mutations in two other genes, CCR2 and SDF-1.vations that soluble gp120 is neurotoxic in cell culture
The benefit conferred by the heterozygous deletion inand in transgenic mice. Because several chemokine re-
CCR5 is thought to result from decreased expressionceptors, including CXCR4, are expressed in the brain, it
levels of the receptor in these patients. The effect ofwill be important to determine the full spectrum of recep-
the mutation in the CCR2 gene is not yet understood,tor specificities of neuropathogenic strains of HIV-1.
particularly because the mutation is in a transmembraneReceptors in Nonhuman Primates. The SIV disease
region and does not affect HIV entry, and because themodel in the Rhesus macaque is currently the best ani-
gene product is used only by a small fraction of viruses.mal model for HIV disease in humans. In both diseases,
However, the CCR2 gene is closely linked to CCR-5,infection results in immunodeficiency and neurodegen-
and a strong linkage disequilibrium has been reportederative disease, and the time to disease onset correlates
for the mutation and a polymorphism in the CCR5 regula-
inversely with the level of plasma viremia during the
tory region. It is therefore possible that the CCR2 muta-
asymptomatic phase. In contrast to HIV-1 strains, which
tion is also associated with lower levels of CCR5 expres-
predominantly utilize CCR5, CXCR4, or both, SIVs do
sion. The effect of the mutation in the gene encoding
not use CXCR4. However, most strains of SIV and many
SDF-1, the only known ligand of CXCR4, is the most
of HIV-2 utilize two orphan GPCRs, Bonzo/STRL33/
difficult to understand. It has been proposed that this
TYMSTR and BOB/GPR15, as efficiently as CCR5 (Deng mutation in the 39 untranslated region of one of the two
et al., 1997). Evolution of receptor tropism in the SIV SDF-1 alternatively spliced isoforms results in a higher
model is not yet well-characterized, and it is unclear if level of chemokine, which may limit infection with X4
transmission and progression to disease are dependent strains in vivo, but this has yet to be substantiated.
on CCR5 or the other receptors. The protective effect has only been clearly observed in
Studies with SIV offer potentially valuable insight into individuals homozygous for the SDF-1 polymorphism.
the role of envelope±receptor interactions in postentry Chemokine Receptors as Potential
events in macrophages. CCR5-specific strains that dif- Therapeutic Targets
fer only in their gp120 sequence differ in their abilities The finding that chemokines can inhibit HIV replication
to replicate in macaque macrophages, even though they by blocking viral entry has provided the impetus to de-
can undergo envelope-mediated fusion equally well velop compounds that will interfere with HIV binding to
(Mori et al., 1993). HIV-1 strains with CCR5 tropism that CCR5 and CXCR4. Because the absence of CCR5 does
replicate in primary activated T cells but not in macro- not appear to result in a significant phenotype, blocking
phages have also been described, although it is unclear of CCR5 function with specific agents is likely to be well
if these can also enter the nonpermissive cells. Interac- tolerated. There is, however, the concern that interfer-
tion of the envelope glycoproteins with structures on ence with viral utilization of CCR5 may accelerate selec-
tion of strains with broader tropism that could potentiallythe macrophage cell surface may thuspotentially initiate
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Doranz, B.J., Grovit-Ferbas, K., Sharron, M.P., Mao, S.H., Goetz,be more pathogenic. This concern is mitigated to some
M.B., Daar, E.S., Doms, R.W., and O'Brien, W.A. (1997). J. Exp. Med.degree by the observed delay in disease progression in
186, 1395±1400.individuals heterozygous for the CCR5D32 allele.
Dumonceaux, J., Nisole, S., Chanel, C., Quivet, L., Amara, A., Baleux,Inhibition of CXCR4 function is likely to be more prob-
F., Briand, P., and Hazan, U. (1998). J. Virol. 72, 512±519.
lematic. Targeted deletion of the murine SDF-1 gene
Edinger, A.L., Mankowski, J.L., Doranz, B.J., Margulies, B.J., Lee,
results in late fetal lethality, abnormal B cell and myeloid B., Rucker, J., Sharron, M., Hoffman, T.L., Berson, J.F., Zink, M.C.,
development, and defective cardiac ventricular septum et al. (1997). Proc. Natl. Acad. Sci. USA 94, 14742±14747.
formation (Nagasawa et al., 1996). It is not known if loss Endres, M.J., Clapham, P.R., Marsh, M., Ahuja, M., Turner, J.D.,
of SDF-1 function in adult animals would be similarly McKnight, A., Thomas, J.F., Stoebenau-Haggarty, B., Choe, S.,
Vance, P.J., et al. (1996). Cell 87, 745±756.detrimental. Several inhibitors of CXCR4 function have
recently been described. One class of compounds, the Feng, Y., Broder, C.C., Kennedy, P E., Berger, E.A. (1996). Science
272, 872±877.bicyclams, were identified in screens for inhibitors of
He, J., Chen, Y., Farzan, M., Choe, H., Ohagen, A., Gartner, S.,HIV replication and were found to block not only virus
Busciglio, J., Yang, X., Hofmann, W., Newman, W., Mackay, C.R.,binding and entry, but also responses to SDF-1 and
Sodroski, J., and Gabuzda, D. (1997). Nature 385, 645±649.binding of an anti-CXCR4 antibody (Donzella et al.,
Heveker, N., Montes, M., Germeroth, L., Amara, A., Trautmann, A.,1998). No effect was observed on infection with R5
Alizon,M., and Schneider-Mergener, J. (1998). Curr. Biol. 8, 369±376.strains of HIV-1. Positively charged peptides consisting
Mori, K., Ringler, D.J., and Desrosiers, R.C. (1993). J. Virol. 67, 2807±of nine arginine residues stabilized by terminal protec-
2814.
tion and inclusion of D±amino acids and of 18 amino
Murakami, T., Nakajima, T., Koyanagi, Y., Tachibana, K., Fujii, N.,
acids stabilized by internal disulfide bonds were simi- Tamamura, H., Yoshida, N., Waki, M., Matsumoto, A., Yoshie, O., et
larly found to block infection with X4 virus as well as al. (1997). J. Exp. Med. 186, 1389±1393.
the response to SDF-1 (Doranz et al., 1997; Murakami Nagasawa, T., Hirota, S., Tachibana, K., Takakura, N., Nishikawa,
et al., 1997). In light of the potential detrimental effect of S., Kitamura, Y., Yoshida, N., Kikutani, H., and Kishimoto, T. (1996).
Nature 382, 635±638.blocking SDF-1 function, the most encouraging results
have been obtained with mutant peptides correspond- Premack, B.A., and Schall, T.J. (1996). Nat. Med. 2, 1174±1178.
ing to the amino-terminal sequence of SDF-1, which Stewart, G. (1998). Nat. Med. 4, 275±277.
had anti-viral activity but no effect on Ca21 fluxing in Weiss, R.A., and Clapham, P.R. (1996). Nature 381, 647±648.
response to chemokine (Heveker et al., 1998). It may Weissman, D., Rabin, R.L., Arthos, J., Rubbert, A., Dybul, M., Swof-
thus be possible to develop compounds that selectively ford, R., Venkatesan, S., Farber, J.M., and Fauci, A.S. (1997). Nature
389, 981±985.block viral entry without affecting thephysiological func-
tion of the receptor.
Future Prospects
Despite the important advances made in studies of
chemokine receptor family members in HIV and SIV en-
try, much remains to be learned of the potential roles
of these receptors in transmission and disease progres-
sion. It will be important to learn if pathogenesis directly
involves the knownreceptors or perhaps even additional
receptors yet to be identified. The normal functions of
such receptors will need to be fully understood, and this
will likely require studies in gene-targeted mice. It is also
unclear if individual receptors have signal-transducing
properties that can be exploited by different viruses. A
combination of studieson the biology of virus replication
in different primary cells and on animal model systems
will be required to address these questions.
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